# Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects

> **NCT02828397** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** REGN2222

## Key facts

- **NCT ID:** NCT02828397
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2016-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02828397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02828397, "Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02828397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*